Summary
With FDA-approved products LUTATHERA and PLUVICTO, both beta-emitters, Novartis has established itself as an industry frontrunner.
Over 15 ongoing or planned trials and several next-generation candidates in development in Novartis RLT pipeline.
Rivals include AstraZeneca, Bayer, Eli Lilly, Curium Pharma, ITM Isotope Technologies, and others.
As radioligand therapy rapidly advances as a promising therapeutic option, Novartis is already demonstrating clear leadership in the field with its approved products, LUTATHERA and PLUVICTO, both of which are beta emitters. LUTATHERA became the first FDA-approved radioligand therapy for adult GEP-NET pa...
